One-prime Multi-Boost Strategy Immunization with Recombinant DNA, Adenovirus, and MVA Vector Vaccines Expressing HPV16 L1 Induces Potent, Sustained, and Specific Immune Response in Mice.

Li,He-Rong Wang,Zhi-Yi Zhou,Jing Luo,Xiang-Qian Xiao,Xiao-Li Wang,Jin-Tao Li,Yu-Bai Zhou,Yi Zeng
DOI: https://doi.org/10.1016/j.antiviral.2016.01.014
IF: 7.6
2016-01-01
Antiviral Research
Abstract:Human papillomavirus (HPV) is associated with various human diseases, including cancer, and developing vaccines is a cost-efficient strategy to prevent HPV-related disease. The major capsid protein L1, which an increasing number of studies have confirmed is typically expressed early in infection, is a promising antigen for such a vaccine, although the E6 and E7 proteins have been characterized more extensively. Thus, the L1 gene from HPV16 was inserted into a recombinant vector, AdHu5, and MVA viral vectors, and administered by prime-boost immunization. Virus-like particles were used as control antigens. Our results indicate that prime-boost immunization with heterologous vaccines induced robust and sustained cellular and humoral response specific to HPV16 L1. In particular, sera obtained from mice immunized with DNA + DNA + Ad + MVA had excellent antitumor activity in vivo. However, the data also confirm that virus-like particles can only elicit low levels cellular immunity and not be long-lasting, and are therefore unsuitable for treatment of existing HPV infections.
What problem does this paper attempt to address?